



**AMENDMENT AND REMARKS RESPONSIVE TO OFFICE ACTION MAILED
MARCH 1, 1999**

In response to the office action mailed March 1, 1999, please amend the application as follows.

In the Specification:

At page 7, line 9, immediately after "75949", add -- or 97525--.

At page 8, line 31, immediately after "75949", add -- or 97525--.

In the Claims:

Please cancel claims 9-10 and add new claims 11-13 to read:

- Gul 2*
G
- 11. An isolated nucleic acid comprising Clone ATCC 68075.—
 - 12. An isolated nucleic acid comprising Clone ATCC 75949.—
 - 13. A isolated fragment of the nucleic acid consisting of a clone selected from the group consisting of Clone ATCC 68075, ATCC 75949, and ATCC 97525, said fragment encoding a peptide that promotes the regeneration of a process of a central or peripheral neuron in vitro.--

REMARKS

Each rejection in the office action is discussed below, with reference to paragraph numbers in the text of the office action.

Paragraphs 1 and 2 require no response.

Paragraph 3 rejects all pending claims (claims 8-10) based on the written description provision of 35 U.S.C. §112 ¶1. The paragraph rejects any reference to ATCC deposit 97525 as new matter and any claims referencing that deposit as lacking written description, because the